Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

The introduction of antibody markers to identify undesired cell populations in flow-cytometry based assays, so called DUMP channel markers, has become a practice in an increasing number of labs performing HLA-peptide multimer assays. However, the impact of the introduction of a DUMP channel in multimer assays has so far not been systematically investigated across a broad variety of protocols.

Methods

The Cancer Research Institute's Cancer Immunotherapy Consortium (CRI-CIC) conducted a multimer proficiency panel with a specific focus on the impact of DUMP channel use. The panel design allowed individual laboratories to use their own protocol for thawing, staining, gating, and data analysis. Each experiment was performed twice and in parallel, with and without the application of a dump channel strategy.

Results

The introduction of a DUMP channel is an effective measure to reduce the amount of non-specific MULTIMER binding to T cells. Beneficial effects for the use of a DUMP channel were observed across a wide range of individual laboratories and for all tested donor-antigen combinations. In 48% of experiments we observed a reduction of the background MULTIMER-binding. In this subgroup of experiments the median background reduction observed after introduction of a DUMP channel was 0.053%.

Conclusions

We conclude that appropriate use of a DUMP channel can significantly reduce background staining across a large fraction of protocols and improve the ability to accurately detect and quantify the frequency of antigen-specific T cells by multimer reagents. Thus, use of a DUMP channel may become crucial for detecting low frequency antigen-specific immune responses. Further recommendations on assay performance and data presentation guidelines for publication of MULTIMER experimental data are provided.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schloot NC, Meierhoff G, Karlsson FM, Ott P, Putnam A, Lehmann P: Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun. 2003, 21: 365-376. 10.1016/S0896-8411(03)00111-2.CrossRefPubMed Schloot NC, Meierhoff G, Karlsson FM, Ott P, Putnam A, Lehmann P: Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun. 2003, 21: 365-376. 10.1016/S0896-8411(03)00111-2.CrossRefPubMed
2.
go back to reference Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D'souza MP: Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005, 21: 68-81. 10.1089/aid.2005.21.68.CrossRefPubMed Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D'souza MP: Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005, 21: 68-81. 10.1089/aid.2005.21.68.CrossRefPubMed
3.
go back to reference Janetzki S, Cox JH, Oden N, Ferrari G: Standardization and validation issues of the ELISPOT assay. Methods Mol Biol. 2005, 302: 51-86.PubMed Janetzki S, Cox JH, Oden N, Ferrari G: Standardization and validation issues of the ELISPOT assay. Methods Mol Biol. 2005, 302: 51-86.PubMed
5.
go back to reference Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A: Toward the harmonization of immune monitoring in clinical trials: Quo vadis?. Cancer Immunol Immunother. 2007, 57: 285-288. 10.1007/s00262-007-0379-z.CrossRefPubMedPubMedCentral Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A: Toward the harmonization of immune monitoring in clinical trials: Quo vadis?. Cancer Immunol Immunother. 2007, 57: 285-288. 10.1007/s00262-007-0379-z.CrossRefPubMedPubMedCentral
6.
go back to reference Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM: Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother. 2008, 57: 303-315. 10.1007/s00262-007-0380-6.CrossRefPubMedPubMedCentral Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM: Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother. 2008, 57: 303-315. 10.1007/s00262-007-0380-6.CrossRefPubMedPubMedCentral
7.
go back to reference Britten CM, Janetzki S, Ben Porat L, Clay TM, Kalos M, Maecker H: Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother. 2009, 58: 1701-1713. 10.1007/s00262-009-0681-z.CrossRefPubMedPubMedCentral Britten CM, Janetzki S, Ben Porat L, Clay TM, Kalos M, Maecker H: Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother. 2009, 58: 1701-1713. 10.1007/s00262-009-0681-z.CrossRefPubMedPubMedCentral
8.
go back to reference Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH: Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One. 2009, 4: e7972-10.1371/journal.pone.0007972.CrossRefPubMedPubMedCentral Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH: Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One. 2009, 4: e7972-10.1371/journal.pone.0007972.CrossRefPubMedPubMedCentral
9.
go back to reference Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI: Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996, 274: 94-96. 10.1126/science.274.5284.94.CrossRefPubMed Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI: Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996, 274: 94-96. 10.1126/science.274.5284.94.CrossRefPubMed
10.
go back to reference Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ: "MIATA"-minimal information about T cell assays. Immunity. 2009, 31: 527-528. 10.1016/j.immuni.2009.09.007.CrossRefPubMedPubMedCentral Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ: "MIATA"-minimal information about T cell assays. Immunity. 2009, 31: 527-528. 10.1016/j.immuni.2009.09.007.CrossRefPubMedPubMedCentral
11.
go back to reference Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI: Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother. 2010, 60: 15-22. 10.1007/s00262-010-0940-z.CrossRefPubMedPubMedCentral Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI: Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother. 2010, 60: 15-22. 10.1007/s00262-010-0940-z.CrossRefPubMedPubMedCentral
12.
go back to reference Smith JG, Joseph HR, Green T, Field JA, Wooters M, Kaufhold RM: Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol. 2007, 14: 527-537. 10.1128/CVI.00435-06.CrossRefPubMedPubMedCentral Smith JG, Joseph HR, Green T, Field JA, Wooters M, Kaufhold RM: Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol. 2007, 14: 527-537. 10.1128/CVI.00435-06.CrossRefPubMedPubMedCentral
13.
14.
go back to reference Coulie PG, van der Bruggen P: T-cell responses of vaccinated cancer patients. Curr Opin Immunol. 2003, 15: 131-137. 10.1016/S0952-7915(03)00009-8.CrossRefPubMed Coulie PG, van der Bruggen P: T-cell responses of vaccinated cancer patients. Curr Opin Immunol. 2003, 15: 131-137. 10.1016/S0952-7915(03)00009-8.CrossRefPubMed
15.
go back to reference Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P: Human T cell responses against melanoma. Annu Rev Immunol. 2006, 24: 175-208. 10.1146/annurev.immunol.24.021605.090733.CrossRefPubMed Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P: Human T cell responses against melanoma. Annu Rev Immunol. 2006, 24: 175-208. 10.1146/annurev.immunol.24.021605.090733.CrossRefPubMed
16.
go back to reference Boddy L, Wilkins MF, Morris CW: Pattern recognition in flow cytometry. Cytometry. 2001, 44: 195-209. 10.1002/1097-0320(20010701)44:3<195::AID-CYTO1112>3.0.CO;2-H.CrossRefPubMed Boddy L, Wilkins MF, Morris CW: Pattern recognition in flow cytometry. Cytometry. 2001, 44: 195-209. 10.1002/1097-0320(20010701)44:3<195::AID-CYTO1112>3.0.CO;2-H.CrossRefPubMed
17.
go back to reference Chan C, Feng F, Ottinger J, Foster D, West M, Kepler TB: Statistical mixture modeling for cell subtype identification in flow cytometry. Cytometry A. 2008, 73: 693-701.CrossRefPubMedPubMedCentral Chan C, Feng F, Ottinger J, Foster D, West M, Kepler TB: Statistical mixture modeling for cell subtype identification in flow cytometry. Cytometry A. 2008, 73: 693-701.CrossRefPubMedPubMedCentral
18.
go back to reference Boedigheimer MJ, Ferbas J: Mixture modeling approach to flow cytometry data. Cytometry A. 2008, 73: 421-429.CrossRefPubMed Boedigheimer MJ, Ferbas J: Mixture modeling approach to flow cytometry data. Cytometry A. 2008, 73: 421-429.CrossRefPubMed
19.
go back to reference Frelinger J, Ottinger J, Gouttefangeas C, Chan C: Modeling flow cytometry data for cancer vaccine immune monitoring. Cancer Immunol Immunother. 2010, 59: 1435-1441. 10.1007/s00262-010-0883-4.CrossRefPubMedPubMedCentral Frelinger J, Ottinger J, Gouttefangeas C, Chan C: Modeling flow cytometry data for cancer vaccine immune monitoring. Cancer Immunol Immunother. 2010, 59: 1435-1441. 10.1007/s00262-010-0883-4.CrossRefPubMedPubMedCentral
Metadata
Title
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols
Publication date
01-12-2011
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-108

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue